ArticleOncotarget2016
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
Jessica E Stine et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
59 papers cite it
this paperpooled itcites it